Valuation: Vericel Corporation

Market Cap 2.06B 1.85B 1.7B 1.54B 2.88B 196B 2.93B 20.25B 8.13B 103B 7.74B 7.57B 325B P/E 2026 *
72.9x
P/E 2027 * 45.7x
Enterprise Value 2.06B 1.85B 1.7B 1.54B 2.88B 196B 2.93B 20.25B 8.13B 103B 7.74B 7.57B 325B EV / Sales 2026 *
6.13x
EV / Sales 2027 * 5.25x
Free-Float
98.81%
Yield 2026 *
-
Yield 2027 * -
1 day-6.18%
1 week-5.34%
Current month+0.30%
1 month+0.30%
3 months-15.44%
6 months+15.92%
Current year+11.80%
1 week 40.01
Extreme 40.01
43.83
1 month 39
Extreme 39
43.83
Current year 28.95
Extreme 28.95
49.32
1 year 28.95
Extreme 28.95
49.32
3 years 28.95
Extreme 28.95
63
5 years 17.3
Extreme 17.3
63
10 years 2
Extreme 2
68.94
Manager TitleAgeSince
Chief Executive Officer 62 2013-02-28
Director of Finance/CFO 51 2021-01-24
Chief Tech/Sci/R&D Officer - 2023-12-31
Director TitleAgeSince
Director/Board Member 71 2005-09-27
Chairman 75 2012-10-04
Director/Board Member 57 2013-08-22
Date Insider Type Main position Quantity % Market Cap. Importance
8/12/26 Exercice

Director

21,000 0.0411%
8/3/26 Exercice

Chief Operating Officer

30,000 0.0587%
7/30/26 Exercice

Controller/Auditor

13,500 0.0264%
Change 5-day change 1-year change 3-year change Capi.($)
-6.18%-5.34%+16.59%+17.10% 2.06B
+3.19%+11.31%+67.86%+150.58% 1,263B
-0.73%+3.56%+44.51%+85.81% 658B
+1.41%+3.24%+29.22%+107.83% 521B
+0.42%+3.20%+54.15%+67.18% 391B
+2.18%+2.93%+73.30%+45.62% 369B
+1.12%+4.52%+35.30%+58.08% 307B
+6.96%+8.86%+11.27%+36.62% 290B
+1.15%+6.09%+59.59%+77.06% 252B
+3.06%+9.38%+44.11%+119.47% 212B
Average +0.94%+4.78%+43.59%+76.53% 426.4B
Weighted average by Cap. +1.19%+6.59%+50.86%+98.27%

Financials

2026 *2027 *
Net sales 336M 301M 277M 251M 469M 31.92B 478M 3.3B 1.33B 16.79B 1.26B 1.23B 52.96B 393M 352M 324M 293M 548M 37.31B 559M 3.86B 1.55B 19.63B 1.47B 1.44B 61.89B
Net income 29.29M 26.23M 24.13M 21.86M 40.87M 2.78B 41.63M 288M 116M 1.46B 110M 108M 4.61B 47.3M 42.36M 38.97M 35.31M 66M 4.49B 67.23M 465M 187M 2.36B 178M 174M 7.45B
Net Debt - -
Projected Income Statement - Annual - Vericel Corporation
Logo Vericel Corporation
Vericel Corporation is a provider of advanced therapies for sports medicine and severe burn care markets. It has a differentiated portfolio of cell therapy and specialty biologic products. It markets three products in the United States. MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous-cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. The Company also holds a license for North American rights to NexoBrid (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns.
Employees
398
Date Price Change Volume
26-10-30 US$40.26 -6.18% 598,735
26-10-29 US$42.91 +4.43% 544,831
26-10-28 US$41.09 -5.04% 680,185
26-10-27 US$43.27 +0.53% 558,366
26-10-26 US$43.04 +1.20% 634,752
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Vericel Corporation
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
40.26USD
Average target price
59.71USD
Spread / Average Target
+48.32%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Vericel Corporation
  1. Stock Market
  2. Stocks
  3. VCEL Stock